The role of Stenotrophomonas maltophilia in refractory chronic rhinosinusitis.
BACKGROUND
Stenotrophomonas maltophilia is a multidrug-resistant Gram-negative bacillus that has been implicated in serious nosocomial infections. This microbe has also been isolated from sinus cultures in refractory chronic rhinosinusitis (CRS). The goal of this study was to elucidate the implications of S. maltophilia-positive cultures in the setting of CRS. The objectives of the study were (1) to define clinical and microbiological characteristics and (2) to assess management strategy and overall outcomes of S. maltophilia-positive sinus cultures in CRS patients.


METHODS
A retrospective review was performed of 101 patients over a 5-year period.


RESULTS
The mean age was 56.9 years with a female/male ratio of 1.1:1. Previous sinus surgery had been performed in 90.1% of patients. Greater than 97% of patients had been given antibiotics in the previous 6 months. The most common presenting symptom was discolored nasal drainage (76.2%) with endoscopic evidence of pus or crusting in 83.2% of cases. Monotherapy with trimethoprim sulfamethoxazole (TMX) or fluoroquinolones was used in 41 and 26%, respectively. This intervention resulted in overall symptom and endoscopic improvement in 70% of cases.


CONCLUSIONS
The presence of S. maltophilia isolates on culture are associated with clinically relevant symptoms and endoscopic findings in patients with refractory CRS. Despite its multidrug-resistant nature, monotherapy with TMX or fluoroquinolones appears to be effective in providing patients with bacterial infection with symptom relief in a majority of cases.
Grindler
David
D
School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Thomas
Charles
C
Hall
Geraldine S
GS
Batra
Pete S
PS
D002908:Chronic Disease; D018450:Disease Progression; D004351:Drug Resistance; D005260:Female; D024841:Fluoroquinolones / Q000627:therapeutic use; D016905:Gram-Negative Bacterial Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010256:Paranasal Sinuses / Q000382:microbiology* / Q000473:pathology / Q000601:surgery; D012220:Rhinitis / Q000150:complications / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology / Q000503:physiopathology; D012852:Sinusitis / Q000150:complications / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology / Q000503:physiopathology; D020615:Stenotrophomonas maltophilia / Q000276:immunology*; D013492:Suppuration / Q000378:metabolism; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
D024841:Fluoroquinolones; D015662:Trimethoprim, Sulfamethoxazole Drug Combination